Strategic partnerships PDL BioPharma recently engaged in partnership activities and credit arrangements with CareView Communications, indicating ongoing collaboration and potential for co-development, licensing, or mutually beneficial financing opportunities with healthcare tech and medtech players.

Legal and IP leverage PDL has a history of pursuing IP-based licensing and compensation related to its technology, including a notable suit against Eli Lilly. This suggests a strong emphasis on monetizing intellectual property, presenting sales angles around licensing, technology transfer, and contract-driven revenue.

Portfolio divestitures Past asset sales and spin-offs, such as LENSAR and Noden Pharma divestitures, indicate a strategy of strategic realignment. This could open opportunities for soluciones that align with PDL’s remaining core assets or facilitate joint ventures around their remaining biotech programs.

Financial scale With annual revenue in the mid hundreds of millions and a sizeable employee base, PDL BioPharma represents a mid-cap biotech profile likely seeking scalable enterprise solutions, financial services, and technology platforms that support growth, compliance, and efficiency.

Technology footprint PDL’s tech stack—WordPress, MongoDB, Zendesk, Microsoft 365 and Azure, PHP, Slack—signals openness to digital infrastructure, customer support optimization, data management, and collaboration tools. There are upsell opportunities for SaaS, cybersecurity, cloud services, and workflow integrations.